Open research library
Every starter record separates community interest, human-evidence work still needed, safety context, and anti-doping context. It is an editorial queue, not a product catalogue.
9 research records
Synthetic peptide discussed in injury and recovery communities
A 2025 two-participant safety pilot and a 2026 ex-vivo human-tissue experiment do not test tendon healing or recovery. An older planned phase-I registration has no posted results. No community-claim efficacy conclusion is supported by these records.
Open research recordThymosin beta-4 fragment discussed in tissue-repair communities
Do not merge TB-500 with full-length thymosin β4. Recent human studies found in this update concern different thymosin β4 molecules/formulations and unrelated eye or early-phase contexts; they are not evidence for TB-500 or recovery claims.
Open research recordGrowth-hormone-releasing hormone analogue
An older randomised study in healthy adults found sustained GH and IGF-I biomarker changes. It did not test muscle gain, fat loss, appearance, performance, recovery, or long-term safety; biomarker change is not a community-claim outcome.
Open research recordGrowth-hormone secretagogue
A phase-II postoperative-ileus study in surgical patients reported no significant difference versus placebo in key or secondary efficacy analyses. It does not test body composition, athletic recovery, or appearance claims.
Open research recordGrowth-hormone fragment discussed in body-composition communities
FDA meeting material summarising historical obesity studies states that the clinical studies reviewed did not show statistically significant weight loss versus placebo and notes limited underlying reporting. This does not test recovery or joint claims.
Open research recordSynthetic peptide discussed in tanning and appearance communities
The direct human paper identified is an early phase-I pilot in three men from 1996. It observed pigmentation and short-term symptoms but is far too small and old to establish safety or a modern appearance-use conclusion.
Open research recordCopper peptide discussed in skin and hair communities
A 2026 ClinicalTrials.gov record describes a recruiting topical wound-healing study, but has no posted results. A planned topical wound study is not evidence for hair, cosmetic appearance, injectable products, or efficacy.
Open research recordGrowth-hormone-releasing factor analogue with a specific U.S. labelled indication
Recent controlled research in people with HIV and metabolic disease found changes in visceral and hepatic fat in that specific clinical population. FDA labelling limits the indication to HIV-associated lipodystrophy and explicitly says it is not for weight-loss management.
Open research recordInvestigational triple hormone-receptor agonist
A 2026 phase-III study in adults with type-2 diabetes reported body-weight and glycaemic outcomes over 40 weeks. This is clinical evidence in a defined medical population, not an individual recommendation or evidence for general appearance goals.
Open research recordSource register
U.S. Food and Drug Administration
Refresh: Editorial review when FDA updates the table
This is a U.S. compounding-safety source; it is not a global authorisation database.
Refresh: Every annual list, plus WADA updates
Verify the applicable List and any Therapeutic Use Exemption requirements with the athlete's anti-doping organisation.
Refresh: Weekdays; check dataTimestamp before ingestion
A registered study is not proof of efficacy, safety, completion, or publication.
Refresh: Quarterly; may lag source data
Reports do not establish causation and cannot estimate event frequency or incidence.
Refresh: Twice daily
Covers EMA website content and centrally authorised medicine material; member-state status can differ.
Refresh: Search on each editorial review; record the search date and exact paper URL
A PubMed record indexes a paper; the study design, population, exact substance, and limits must still be extracted from that paper.
ClinicalTrials.gov / U.S. National Library of Medicine
Refresh: Recheck status and results before each publication update
A registration is not a result. Study descriptions are supplied by the responsible party; no-result records must never be presented as efficacy or safety evidence.
U.S. Food and Drug Administration
Refresh: When FDA updates the related compounding review or meeting materials
The AOD-9604 discussion summarises submitted literature and identifies important limitations; it is not a peer-reviewed primary study report.
U.S. Food and Drug Administration
Refresh: Check Drugs@FDA before each status update
The labelled indication is limited to reduction of excess abdominal fat in adults with HIV-associated lipodystrophy; the label states it is not indicated for weight-loss management.